The crux for valuation of Medizone is the ability to defend its patents. Following is a quote describing the situation MZEI faces. I forget the source.
“Today, the purpose of the patent system is to lock small companies out of markets which big companies find very profitable. The system is doing what big-company lobbyists want it to do. Since most legislation is written, in effect, by lobbyists, there is no chance that this will change anytime soon.”
If Medizone tries to “go it alone” their patents will be considerably infringed upon; the Company will lack the ability to effectively defend them; and the Company’s value will be modest compared to its value if bought out.
I believe Ed Marshall understands this and, once our production machine is ready for sale, has every intention of selling out at that point. This would explain his failure to bring in the manpower and talent to operate an on-going business. Talent that had been brought in, say, six months ago, would have to have been told they would be out of a job when the Company would be sold in, say, six months from now. The only talent he needs is assistance in marketing the Company and negotiating the sale.
